OSL Stock Overview
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
OncoSil Medical Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.005 |
52 Week High | AU$0.015 |
52 Week Low | AU$0.005 |
Beta | 0.42 |
1 Month Change | -37.49% |
3 Month Change | -44.44% |
1 Year Change | -54.54% |
3 Year Change | -94.68% |
5 Year Change | -91.07% |
Change since IPO | -97.50% |
Recent News & Updates
Recent updates
Companies Like OncoSil Medical (ASX:OSL) Could Be Quite Risky
May 24Here's Why We're Watching OncoSil Medical's (ASX:OSL) Cash Burn Situation
Feb 03Is OncoSil Medical (ASX:OSL) In A Good Position To Deliver On Growth Plans?
Oct 20OncoSil Medical (ASX:OSL) Is In A Good Position To Deliver On Growth Plans
May 13OncoSil Medical's (ASX:OSL) Stock Price Has Reduced 42% In The Past Five Years
Mar 21We're Not Worried About OncoSil Medical's (ASX:OSL) Cash Burn
Jan 26How Much Did OncoSil Medical's(ASX:OSL) Shareholders Earn From Share Price Movements Over The Last Year?
Dec 04Shareholder Returns
OSL | AU Life Sciences | AU Market | |
---|---|---|---|
7D | -16.7% | 3.3% | 1.3% |
1Y | -54.5% | -22.8% | 11.5% |
Return vs Industry: OSL underperformed the Australian Life Sciences industry which returned -22.8% over the past year.
Return vs Market: OSL underperformed the Australian Market which returned 11.5% over the past year.
Price Volatility
OSL volatility | |
---|---|
OSL Average Weekly Movement | 25.4% |
Life Sciences Industry Average Movement | 10.0% |
Market Average Movement | 8.8% |
10% most volatile stocks in AU Market | 17.1% |
10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: OSL's share price has been volatile over the past 3 months.
Volatility Over Time: OSL's weekly volatility has increased from 19% to 25% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | n/a | Nigel Lange | https://www.oncosil.com.au |
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
OncoSil Medical Limited Fundamentals Summary
OSL fundamental statistics | |
---|---|
Market cap | AU$9.87m |
Earnings (TTM) | -AU$11.71m |
Revenue (TTM) | AU$1.30m |
7.6x
P/S Ratio-0.8x
P/E RatioIs OSL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
OSL income statement (TTM) | |
---|---|
Revenue | AU$1.30m |
Cost of Revenue | AU$1.87m |
Gross Profit | -AU$573.73k |
Other Expenses | AU$11.13m |
Earnings | -AU$11.71m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0059 |
Gross Margin | -44.18% |
Net Profit Margin | -901.58% |
Debt/Equity Ratio | 0% |
How did OSL perform over the long term?
See historical performance and comparison